Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Ribociclib

Drug and asset intelligence for Ribociclib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Stage
Development stage unavailable

Sponsor company

Novartis Pharmaceuticals →

Mechanism of action

Radioligand Therapy

Recent signals(2)

ClinicalAugust 14, 2026

Phase III Trial Comparing Ribociclib with Chemotherapy in High Stage Breast Cancer

A phase III trial, sponsored by the National Cancer Institute, is currently evaluating the efficacy of hormone therapy combined with ribociclib against chemotherapy followed by hormone therapy in patients diagnosed with high anatomic stage breast cancer characterized by low recurrence risk.

ClinicalAugust 8, 2026

[177Lu]Lu-NeoB Trial with Ribociclib and Fulvestrant in ER+, HER2- Advanced Breast Cancer

A trial is underway to estimate the recommended dose of [177Lu]Lu-NeoB combined with ribociclib and fulvestrant for advanced breast cancer patients.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Breast Cancer →

Therapeutic areas

Breast Cancer →
Oncology →
Radioligand Therapy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.